Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Breaking: positive results from the VIKTORIA-1 PIK3CA-mutant cohort
Both the gedatolisib triplet and doublet improved PFS vs fulv/alpelisib, positioning gedatolisib as an active option irrespective of PIK3CA status.
Key caveat: the weekly IV formulation.”
